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Selective suppression of protein function in the brain can be achieved using specific silenc-
ing RNAs administered in vivo. A viral delivery system is often employed to transfect
neurons with small hairpin RNA (shRNA) directed against specific proteins, and intervals
of several days are allowed between microinjection of the shRNA-containing virus into
the brain and experiments to assess suppression of gene function. Here we report stud-
ies using extracellular recording of dopaminergic neurons of the ventral tegmental area
(DA VTA neurons) recorded in brain slices in which lentivirus containing shRNA directed
against Gq was included in the recording pipette, and suppression of Gq-related function
was observed within the time frame of the recording. The action of neurotensin (NT) is
associated with activation of Gq, and the firing rate of DA VTA neurons is increased by NT.
With shRNA directed against Gq in the pipette, there was a significant reduction of NT
excitation within 2 h. Likewise, time-dependent dopamine desensitization, which we have
hypothesized to be Gq-dependent, was not observed when shRNA directed against Gq
was present in the pipette and dopamine was tested 2 h after initiation of recording. As the
time interval (2 h) is relatively short, we tested whether blockade of protein synthesis with
cycloheximide delivered via the recording pipette would alter Gq-linked responses similarly.
Both NT-induced excitation and dopamine desensitization were inhibited in the presence of
cycloheximide. Inclusion of shRNA in the recording pipette may be an efficient and selective
way to dampen responses linked to Gq, and, more generally, the use of lentiviral-packaged
shRNA in the recording pipette is a means to produce selective inhibition of the function
of specific proteins in experiments.
Keywords: desensitization, dopamine D2 receptor, ventral tegmental area, neurotensin, Gq, shRNA, lentivirus
INTRODUCTION
In receptor-based pharmacology, specific antagonists are usually
used to reduce receptor function to help understand the role of that
receptor in physiological processes (Cooper et al., 1996). Other
pharmacological agents can be used to interfere with intracellu-
lar processes, such as second messenger activation (e.g., diacyl-
glycerol) or the subsequent actions of those second messengers
on other intracellular signaling proteins (e.g., protein kinase C;
Nishizuka, 2001). One aspect of the use of such agents is that they
are often not specific enough to distinguish among protein iso-
forms. Currently, the most specific means to interfere with protein
or neurotransmitter action is to alter the expression of a spe-
cific gene product. Knockout or knockin mice, for example, have
been developed to assess the role of GABA receptor subtypes in
the responses to alcohol and other agents (Borghese et al., 2006;
Halonen et al., 2009).
Complications with developmental adaptation as a result of
knockouts have led to the development of conditional and
inducible knockouts, in which knockouts can be limited to a
specific brain region (conditional) or treatment with agents
such as certain antibiotics (inducible) lead to interference with
transcription of specific gene products in specific brain areas or
at a specific postnatal time. These methods are costly, as mak-
ing gene modifications and breeding of appropriate subjects can
require a lot of time and resources (e.g., animal housing and main-
tenance). In addition, efficiency of knockout of specific genes may
vary depending on the gene locus and Cre activity in specific cells
(Sauer, 1998). Acute delivery of small hairpin RNA (shRNA) can
reduce gene expression selectively. This method employs short
strands of RNA that contains a tight hairpin formation and that
are designed to bind specifically to regions of the mRNA coding the
protein of interest. Binding of the shRNA is sufficient to suppress
translation of the protein (Burnett and Rossi, 2012). Because of the
specificity of the shRNA sequence, this method can be much more
selective than receptor-based pharmacological methods. Gener-
ally, the shRNA is packaged within a viral or bacterial vector to
facilitate entry into the cell. Most published methods indicate that
the time frame needed for adequate suppression of function is on
the order of days (Gupta et al., 2004) and sometimes may not be
long-lived (Davidson and Boudreau, 2007).
The actions of many neurotransmitters are mediated by
G-protein coupled receptors; stimulation of neurotransmitter
receptors results in activation of specific G-proteins, which in turn
modify the activity of ion channels or intracellular enzymes like
Frontiers in Cellular Neuroscience www.frontiersin.org February 2013 | Volume 7 | Article 7 | 1
Nimitvilai et al. Micropipette shRNA delivery suppresses Gq
kinases. A variety of neurotransmitter receptors are linked to the
activation of a specific G-protein, Gq, including neurotensin (NT),
serotonin, and dopamine receptors. Activation of these receptors
results in activation of Gq, which in turn can initiate the intracel-
lular signaling cascade involving phosphatidylinositol and protein
kinase C (Rashid et al., 2007a). The half-life of Gq in some prepa-
rations has been shown to be on the order of 3–4 h (Mitchell et al.,
1993; Johansson et al., 2005). Specific pharmacological antagonists
of intracellular components like Gq are often difficult to obtain or
unavailable, so it is difficult to demonstrate the specific involve-
ment of such intracellular factors in receptor-mediated processes.
One agent that has been reported to inhibit Gq by selectively inter-
fering with GDP/GTP exchange (YM-254890; Taniguchi et al.,
2003; Takasaki et al., 2004) has limited availability. The goal of
the present study was to suppress the expression of Gq by acute
application of lentivirus containing shRNA against Gq. We have
recently published a number of papers in which pharmacolog-
ical agonists and antagonists were included in the extracellular
recording pipette in order to alter cell function (Nimitvilai et al.,
2012a,c). In the present study, we assessed the feasibility of deliver-
ing lentivirus containing shRNA directed against Gq to a brain slice
preparation directly via the recording electrode during extracellu-
lar electrophysiological experiments, and measuring the responses
to Gq-related pharmacological phenomena. This method had the
advantage of being able to measure the time course over which
we could observe any possible reduction of Gq-related func-
tion. For comparison, in similar experiments, we assessed the
effect of blocking transcription of all proteins by the inclusion
of cycloheximide in the recording pipette.
MATERIALS AND METHODS
ANIMALS
Male Fischer 344 (F344; 90–150 gm) used in these studies were
obtained from Harlan Sprague-Dawley (Indianapolis, IN, USA).
All rats were treated in strict accordance with the NIH Guide for
the Care and Use of Laboratory Animals and all experimental
methods were approved by the Animal Care Committee of the
University of Illinois at Chicago.
PREPARATION OF BRAIN SLICES
The technique for preparing brain slices containing the ventral
tegmental area (VTA) has been described previously (Brodie et al.,
1999). Following rapid removal of the brain, the tissue was blocked
coronally to contain the VTA and substantia nigra. The tissue
block was mounted in the vibratome and submerged. Coronal
sections (400µm thick) were cut in chilled cutting solution using
a vibratome, and the slices were placed onto a mesh platform
in the recording chamber. The slice was submerged in artificial
cerebrospinal fluid (aCSF) maintained at a flow rate of 2 ml/min
and a temperature of 35˚C. The composition of the aCSF in these
experiments was (in mM): NaCl 126, KCl 2.5, NaH2PO4 1.24,
CaCl2 2.4, MgSO4 1.3, NaHCO3 26, glucose 11. The composition
of the cutting solution in the vibratome was (in mM): KCl 2.5,
CaCl2 2.4, MgSO4 1.3, NaHCO3 26, glucose 11, and sucrose 220.
Both solutions were saturated with 95% O2/5% CO2 (pH= 7.4).
Equilibration time of at least 1 h was allowed after placement of
tissue in the recording chamber before electrodes were placed in
the tissue.
CELL IDENTIFICATION
The VTA was clearly visible in the fresh tissue as a gray area medial
to the darker substantia nigra, and separated from the nigra by
white matter. Recording electrodes were placed in the VTA under
visual control. pDAergic neurons have been shown to have distinc-
tive electrophysiological characteristics (Grace and Bunney, 1984;
Lacey et al., 1989). Only those neurons which were anatomically
located within the VTA and which conformed to the criteria for
pDAergic neurons established in the literature and in this labora-
tory (Lacey et al., 1989; Mueller and Brodie, 1989) were studied.
These criteria include broad action potentials (2.5 ms or greater,
measured as the width of the bi- or tri-phasic waveform at the
baseline), slow spontaneous firing rate (0.5–5 Hz), and a regular
interspike interval. Cells were not tested with opiate agonists as has
been done by other groups to further characterize and categorize
VTA neurons (Margolis et al., 2006). It should be noted that some
neurons with the characteristics we used to identify dopaminergic
neurons of the ventral tegmental area (DA VTA neurons) may not,
in fact, be DA-containing (Margolis et al., 2006), and therefore the
DA VTA neurons are referred to as putative DA (pDAergic) VTA
neurons. A recent study (Chieng et al., 2011) provides some con-
fidence that neurons with the electrophysiological characteristics
noted above are, in fact, dopamine-containing.
DRUG ADMINISTRATION
When drugs were added to the aCSF, this was done by means of
a calibrated infusion pump from stock solutions 100–1000 times
the desired final concentrations. The addition of drug solutions
to the aCSF was performed in such a way as to permit the drug
solution to mix completely with aCSF before this mixture reached
the recording chamber. Final concentrations were calculated from
aCSF flow rate, pump infusion rate, and concentration of drug
stock solution. The small volume chamber (about 300µl) used
in these studies permitted the rapid application and washout of
drug solutions. Typically drugs reach equilibrium in the tissue after
2–3 min of application.
In most experiments described here, drugs and lentivirus were
added to the microelectrode filling solution (0.9% NaCl, about
23µl per pipette). To assure effective concentrations of drugs were
delivered to the neurons of interest, we used concentrations higher
than would be used with bath application; the relatively high resis-
tance pipette permits a gradual diffusion into the brain slice, so the
drugs are diluted to an unknown concentration. When both drug
application methods were tested, this pipette-application method
(using higher intra-pipette concentrations) has produced results
comparable to the bath application method (data not shown),
with the advantage of more localized drug application and reduced
expense. Such local delivery of drugs through recording pipettes
has been used by our lab and others (Pesavento et al., 2000;
Nimitvilai et al., 2012a).
DA hydrochloride, NT, and most of the salts used to prepare
the extracellular media were purchased from Sigma (St. Louis,
MO, USA). Cycloheximide was purchased from Tocris (Ellisville,
MO, USA). Lentiviral particles and shRNA incorporated into that
lentivirus were purchased from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA, USA). The lentiviral particles used in these
studies contained three to five expression constructs each encod-
ing target-specific 19–25 nt (plus hairpin) shRNA designed to
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knockdown gene expression. Specific particles that were used were
Gαq shRNA (sc-45998-V) and Golf shRNA (sc-108047-V).
For the Gαq shRNA, the lentiviral particles contained a pool
of three different shRNA plasmids (A, B, and C). The sequence
information is (Note: all sequences are provided in 5′→ 3′
orientation):
sc-45998-VA:
Hairpin sequence:
GATCCGCTATCTGACTCTACCAAATTCAAGAGATTTGGT
AGAGTCAGATAGCTTTTT
Corresponding siRNA sequences (sc-45998A):
• Sense: GCUAUCUGACUCUACCAAAtt
• Antisense: UUUGGUAGAGUCAGAUAGCtt
sc-45998-VB:
Hairpin sequence:
GATCCGCTTAGCGAATACGATCAATTCAAGAGATTGATC
GTATTCGCTAAGCTTTTT
Corresponding siRNA sequences (sc-45998B):
• Sense: GCUUAGCGAAUACGAUCAAtt
• Antisense: UUGAUCGUAUUCGCUAAGCtt
sc-45998-VC:
Hairpin sequence:
GATCCGGAGTACAATCTGGTCTAATTCAAGAGATTAGAC
CAGATTGTACTCCTTTTT
Corresponding siRNA sequences (sc-45998C):
• Sense: GGAGUACAAUCUGGUCUAAtt
• Antisense: UUAGACCAGAUUGUACUCCtt
Each siRNA sequence targets mRNA accession NM_031036.
The locations are nucleotides 456 (Strand A), 693 (Strand B), and
1062 (Strand C) of NM_031036.
For the Golf shRNA, the lentiviral particles contained a pool
of three different shRNA plasmids (A, B, and C). The sequence
information is (Note: all sequences are provided in 5′→ 3′
orientation):
sc-108047-VA:
Hairpin sequence:
GATCCGTACAGACCACAAGATGTATTCAAGAGATACATC
TTGTGGTCTGTACTTTTT
Corresponding siRNA sequences (sc-108047A):
• Sense: GUACAGACCACAAGAUGUAtt
• Antisense: UACAUCUUGUGGUCUGUACtt
sc-108047-VB:
Hairpin sequence:
GATCCGTAGTATCTGCCCATCTTATTCAAGAGATAAGA
TGGGCAGATACTACTTTTT
Corresponding siRNA sequences (sc-108047B):
• Sense: GUAGUAUCUGCCCAUCUUAtt
• Antisense: UAAGAUGGGCAGAUACUACtt
sc-108047-VC:
Hairpin sequence:
GATCCCCAACCATCCCTTAGTTAATTCAAGAGATTAAC
TAAGGGATGGTTGGTTTTT
Corresponding siRNA sequences (sc-108047C):
• Sense: CCAACCAUCCCUUAGUUAAtt
• Antisense: UUAACUAAGGGAUGGUUGGtt
Each siRNA sequence targets mRNA accession XM_001060758.
The locations are nucleotides 2682 (Strand A), 2842 (Strand B),
and 3130 (Strand C) of XM_001060758.
EXTRACELLULAR RECORDING
Extracellular recording was chosen for these studies as this method
permits the recordings to be stable and of long duration and allows
us to assess the effects of extended exposure (>2 h) to drugs.
The limitation of only measuring spontaneous action potential
frequency (rather than membrane potential or other electrophysi-
ological parameters) is counterbalanced by the advantage of being
able to determine the time course of drug actions and interactions.
Extracellular recording electrodes were made from 1.5 mm diame-
ter glass tubing with filament and were filled with 0.9% NaCl with
the addition of drugs of interest or appropriate control vehicle. Tip
resistance of the microelectrodes ranged from 2 to 4 MΩ. A Fin-
tronics amplifier was used in conjunction with an IBM-PC-based
data acquisition system (ADInstruments, Inc.). Offline analysis
was used to calculate, display, and store the frequency of firing
1 min intervals. Additional software was used to calculate the fir-
ing rate over 5 s intervals. Firing rate was determined before and
during drug application. Firing rate was calculated over 1 min
intervals prior to administration of drugs and during the drug
effect; peak drug-induced changes in firing rate were expressed
as the percentage change from the control firing rate according
to the formula [(FRD− FRC)/FRC]× 100, where FRD is the fir-
ing rate during the peak drug effect and FRC is the control firing
rate. The change in firing rate thus is expressed as a percentage
of the initial firing rate, which controls for small changes in firing
rate which may occur over time. This formula was used to cal-
culate both excitatory and inhibitory drug effects. Peak excitation
was defined as the peak increase in firing rate produced by the
drug (e.g., NT) greater than the pre-drug baseline. Inhibition was
defined as the lowest firing rate below the pre-drug baseline. Inhi-
bition reversal was observed as a statistically significant reduction
in the inhibition.
DATA COLLECTION
For comparison of the time course of effects on firing rate, the data
were normalized and averaged. Firing rates over 1 min intervals
were calculated and normalized to the 1-min interval immediately
prior to the DA administration. These normalized data were aver-
aged by synchronizing the data to the DA administration period,
and graphs of the averaged data were made.
STATISTICAL ANALYSIS
Averaged numerical values were expressed as the mean± SEM.
Differences in firing rate over 2 h exposure to pipette contents
were assessed using a paired t -test. Differences in the concentra-
tion of DAergic agonists and in the percentage inhibition among
the groups were assessed with one-way ANOVA, followed by Tukey
post hoc comparison. The differences among firing rates during the
long drug administration intervals in these studies was assessed
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with two-way repeated measures ANOVA, followed by Student–
Newman–Keuls or Tukey post hoc comparisons when needed
(Kenakin, 1987). Pooled data in the figures below are expressed as
relative change in firing rate; this permits normalization of the data
to the inhibitory effect of dopamine at the first time point (5 min),
and reflects the statistical analysis, which compared the effects of
dopamine at each time point over time. Statistical analyses were
performed with Origin 8.5 (Originlab Corporation, Northamp-
ton, MA, USA) or Sigmaplot 12 (Systat Software, Inc., San Jose,
CA, USA).
RESULTS
VTA NEURON CHARACTERISTICS
A total of 72 VTA neurons were examined. Their initial firing rate
ranged from 0.73 to 4.1 Hz, with a mean of 2.08± 0.08 Hz. All neu-
rons had regular firing rates, and those cells exposed to dopamine
were inhibited by it. Neurons tested with NT were exposed to the
contents of the recording pipette for at least 2 h and cells were
tested with dopamine only after 2 h of exposure to the contents
of the recording pipette. The mean change in firing rate produced
by this 2-h exposure is shown in Table 1; there was no significant
difference in firing rate from the baseline rate at the initiation of
the recordings and the rate at the 2-h time point in any of the
experimental protocols (paired t -test, p> 0.05 for all groups).
In neurons tested with NT, the concentration of NT was
adjusted so that the firing rate of the VTA neuron was increased
by about 50% during the first 10 min of the recording; that same
concentration of NT was re-applied to that cell throughout the
experiment. In neurons tested for dopamine-induced desensitiza-
tion, sensitivity to dopamine (0.5–10µM) was adjusted for each
neuron so that inhibition exceeded 50%, as inhibition that was
less than 50% was not reliably reversed (Nimitvilai and Brodie,
2010). This method of adjusting the concentration of DAergic ago-
nist controlled for differences in sensitivity between neurons, but
also sometimes resulted in the mean concentrations of dopamine
slightly differing between groups. Overall, for pDAergic VTA neu-
rons from adult rats, the concentration of dopamine used was
5.6± 0.5µM (n= 39) which produced a mean change in fir-
ing rate of −74.4± 2.7% after 5 min of exposure to dopamine.
There were no significant differences in the concentration of DAer-
gic agonists [one-way ANOVA, F (4,34)= 1.94, p> 0.05] or in the
percentage inhibition [one-way ANOVA, F (4,34)= 1.08, p> 0.05]
among the groups. Cells which did not return to at least 70%
of their pre-DA firing rate during this washout were not used.
One benefit of the extracellular recording method used in these
studies is that long duration recordings can be made reliably; the
average recording duration was 171.8± 5.8 min, with a range of
125–270 min.
NEUROTENSIN EXCITATION IS REDUCED BY Gq shRNA
Neurotensin is a major neurotransmitter in the VTA, and may play
a role in regulating DAergic neurons during reward and reinforce-
ment (Rompre et al., 1992). NT effects are mediated by activation
of a Gq-linked receptor that is highly expressed in midbrain DAer-
gic neurons (Palacios and Kuhar, 1981); NT increases firing rate
of DAergic VTA neurons and dopamine release (Kalivas et al.,
1983; Seutin et al., 1989; Farkas et al., 1997). We tested whether
delivery of lentivirus containing shRNA directed against Gq via
the recording pipette would alter NT-induced excitation of DA
VTA neurons. Recordings were made with a pipette containing
lentivirus containing shRNA directed against Gq (1× 105 IFU per
500µl; about 23µl per pipette). Five minutes after a recording of
a DA VTA neuron was initiated, NT (a concentration sufficient
to cause an increase in firing rate of approximately 50%, concen-
tration from 5 to 50 nM, mean concentration 8.93± 1.7 nM) was
added to the superfusate for 5 min and washed out for 30 min.
The same concentration of NT was re-tested in this way at 30 min
intervals. Typical results are shown in Figure 1A. It can be seen
in this Figure that the effect of acute application of NT decreased
over the time of the recording from 25.99% excitation to 2.7%.
When lentivirus without shRNA was included in the recording
pipette (1× 105 IFU per 500µl; about 23µl per pipette), there
was no significant diminution of the magnitude of NT-induced
excitation over time (Figure 1B). The mean results of experi-
ments using pipettes with lentivirus (with and without shRNA)
are shown in Figure 1C. Note that there was a significant inter-
action of shRNA and time [two-way repeated measures ANOVA,
F (3,83)= 7.69, p< 0.001], and there was a significant difference
Table 1 | Change in baseline firing rate over 2 h of recording with micropipettes containing lentivirus and/or shRNA.
Condition Starting baseline (Hz) Baseline at 2 h (Hz) Change in firing rate over pre-treatment period (%)
Figure 1C
Gq shRNA+neurotensin 2.81±0.29 2.18±0.31 −15.0±±9.3
Lentiviral control+neurotensin 2.32±0.36 3.11±0.43 14.8±10.55
Figure 2D
Lentiviral control+dopamine 1.96±0.19 1.81±0.11 −3.53±6.73
Golf+dopamine 2.36±0.24 2.36±0.26 −0.9±5.7
Gq shRNA+dopamine 1.59±0.22 1.46±0.17 6.39±5.71
Figure 3E
Cycloheximide+neurotensin 1.86±0.43 2.09±0.8 18.5±12.36
1% DMSO+neurotensin 2.25±0.31 1.9±0.35 −17.59±7.3
Figure 3F
1% DMSO+dopamine 2.23±0.12 2.17±0.17 −2.19±6.57
Cycloheximide+dopamine 2.47±0.45 2.09±0.36 −7.65±3.4
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FIGURE 1 | Reduction of neurotensin-induced excitation of VTA
neurons by Gq shRNA. (A,B) Ratemeter diagrams. Firing rate over 5 s
intervals is represented by the height of the vertical bars; duration of
drug application is shown by the horizontal bars. Neurotensin (10 nM,
5 min applications) was tested at 30 min intervals while recording from
DA VTA neurons with micropipettes containing 0.9% NaCl to which
either lentivirus containing Gq shRNA (A) or lentivirus without shRNA
(B) was added. The magnitude of neurotensin excitation over time in
the recording shown in (A) was 25.99, 19.33, 8.3, and 2.7%,
respectively; the magnitude of neurotensin excitation over time in the
recording shown in (B) was 58.5, 62.8, 61.3, and 56.4%, respectively.
(C) Bars representing the mean responses to neurotensin in
recordings similar to those shown in (A,B). Mean excitatory effect of
neurotensin is shown at each time period for cells recorded with
micropipettes to which Gq shRNA (filled bars) or lentiviral control (open
bars) was added. There was a significant change in the excitatory
effect of neurotensin in recordings in which Gq shRNA was present in
the micropipettes.
between Gq shRNA and control groups (Tukey post hoc for differ-
ence between 140 min time point vs. 10 min time point: p< 0.05).
These results indicate that inclusion of lentivirus containing Gq
shRNA in the recording pipette resulted in a reduction of the effect
of NT to excite DA VTA neurons.
DIR IS SUPPRESSED BY Gq shRNA
We have recently published a number of papers characterizing the
phenomenon of desensitization of responses to dopamine over
time, a phenomenon which we have termed “dopamine inhibi-
tion reversal” (DIR; Nimitvilai and Brodie, 2010). We have shown
that this phenomenon requires activation of both D2 and D1/D5
receptors (Nimitvilai and Brodie, 2010), is dependent on acti-
vation of phospholipase C and conventional protein kinase C
pathway(Nimitvilai et al., 2012a,c), and is similar to a phenomenon
reported to be linked to activation of Gq (Rashid et al., 2007b;
So et al., 2009). In the present study, we tested whether inclu-
sion of lentivirus with Gq shRNA could alter the development
of DIR. One such experiment is shown in Figure 2A. After 2 h
of recording with a micropipette containing Gq shRNA packaged
in lentivirus (1× 105 IFU per 500µl), we applied dopamine for
40 min; the inhibition produced by dopamine did not subside
over time. In contrast, if lentivirus that did not contain shRNA
was included in the micropipette (1× 105 IFU per 500µl), we
saw a clear reversal of the dopamine-induced inhibition over the
40-min time period of administration (Figure 2B) similar to the
phenomenon of DIR that we have described previously (Nimitvi-
lai and Brodie, 2010; Nimitvilai et al., 2012a,b,c, 2013). Likewise,
if lentivirus containing shRNA directed against a different G-
protein, Golf, was included in the pipette (1× 105 IFU per 500µl),
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FIGURE 2 | Blockade of dopamine inhibition reversal by Gq shRNA. (A–C)
Ratemeter diagrams. Firing rate over 5 s intervals is represented by the height
of the vertical bars; duration of drug application is shown by the horizontal
bars. Recordings were maintained for 2 h before dopamine was applied for
40 min. Recordings were made from DA VTA neurons with micropipettes
containing 0.9% NaCl to which either lentivirus containing Gq shRNA (A),
lentivirus without shRNA (B), or lentivirus containing Golf shRNA (C) was
added. The inhibition produced by dopamine subsided over time when
lentivirus without shRNA or lentivirus containing Golf shRNA was present in
the pipette. No reversal of dopamine-induced inhibition was observed when
lentivirus containing Gq shRNA was in the micropipette. (D) Relative change
in firing rate (mean±SEM) is plotted as a function of time. In experiments
similar to those shown in parts (A–C) above, the effect of dopamine at each
time point was normalized by subtracting the change in firing rate (%) at the
5-min time point. There was a significant reversal in dopamine-induced
inhibition when either Golf shRNA (H) or lentiviral control () was present in
the micropipettes. A significant inhibition produced by dopamine was
observed with the inclusion of Gq shRNA (•) in the micropipettes.
dopamine inhibition subsided over time (Figure 2C), again illus-
trating DIR that is observed under control conditions, and which
we have described extensively previously. Golf shRNA was used
instead of a scrambled shRNA control, and the lack of effect on
DIR suggests that simply including shRNA in the pipette is insuf-
ficient to block DIR. The pooled data from experiments similar
to these three examples is shown in Figure 2D. The magnitude
of the dopamine response over time in comparison to the effect
of dopamine at the 5-min time point is shown on this graph.
A change in the positive direction indicates a decreasing effect
of dopamine with time (DIR); a change in the negative direc-
tion indicates a greater inhibitory effect of dopamine with time.
There was a significant difference in dopamine-induced inhibition
with time [two-way repeated measures ANOVA, F (12,223)= 3.24,
p< 0.001]; Tukey post hoc comparison indicated for all times
between 25 and 40 min that there was no difference (p> 0.05)
between the Golf shRNA group and the control shRNA group,
but there was a significant difference (p< 0.05) between the
Gq shRNA group and both of the other groups (Figure 2D).
These results indicate that DIR was blocked when Gq shRNA was
included in the pipette, and not blocked by the inclusion of Golf
shRNA.
BOTH NEUROTENSIN-INDUCED EXCITATION AND DIR ARE
SUPPRESSED BY CYCLOHEXIMIDE
If the changes observed with the lentiviral vector containing
shRNA ultimately were due to decreased expression of Gq protein,
suppression of overall protein synthesis should also produce a
reduction in NT-induced excitation and DIR. While this does not
necessarily confirm the efficacy of shRNA in the previous experi-
ments, it is important to establish the fact that even non-specific
suppression of protein synthesis can impair Gq-related functions.
To test this hypothesis, we performed extracellular recordings with
pipettes containing cycloheximide (800µM) or 1% DMSO in
0.9% saline. Five minutes after initiating a recording, NT (concen-
tration from 25 to 100 nM, mean concentration 75± 11.18 nM)
was administered for 5 min and then again every 30 min for 2 h,
to compare with the shRNA experiments (Figure 1). Examples
of such experiments are shown in Figures 3A,B. In the pres-
ence of cycloheximide, acute application of NT initially increased
the firing rate by 78.2%, and the effect of NT decreased over the
time of the recording to 15.0% at 110 min (Figure 3A). Without
cycloheximide, no diminution of the magnitude of NT-induced
excitation was observed over time (Figure 3B). In the pool of
recordings with cycloheximide-containing pipettes (Figure 3E),
Frontiers in Cellular Neuroscience www.frontiersin.org February 2013 | Volume 7 | Article 7 | 6
Nimitvilai et al. Micropipette shRNA delivery suppresses Gq
FIGURE 3 | Effect of cycloheximide on neurotensin excitation and DIR.
(A–D) Ratemeter diagrams. Firing rate over 5 s intervals is represented by
the height of the vertical bars; duration of drug application is shown by the
horizontal bars. (A,B) Neurotensin (100 nM) was applied for 5 min at
30 min intervals while recording from DA VTA neurons with micropipettes
containing 0.9% NaCl to which either cycloheximide (A) or vehicle (B) was
added. The magnitude of neurotensin excitation over time in the recording
shown in (A) was 78, 17, 11.7, and 15%, respectively; the magnitude of
neurotensin excitation over time in the recording shown in (B) was 55.4,
40.6, 43.2, and 52.8%, respectively. (C,D) Recordings were maintained for
2 h before dopamine was applied for 40 min. Recordings were made from
DA VTA neurons with micropipettes containing 0.9% NaCl to which either
cycloheximide (C) or vehicle (D) were added. The inhibition produced by
dopamine subsided over time when vehicle was present in the pipette. No
reversal of dopamine-induced inhibition was observed when
cycloheximide was included in the micropipette. (E) Bars representing the
mean responses to neurotensin in recordings similar to those shown in
(A,B). Mean excitatory effect of neurotensin is shown at each time period
for cells recorded with micropipettes to which cycloheximide (filled bars)
or vehicle (open bars) was added. There was a significant reduction in the
excitatory effect of neurotensin in recordings in which cycloheximide was
present in the micropipettes. (F) Relative change in firing rate
(mean±SEM) is plotted as a function of time. In experiments similar to
those shown in (C,D) above, the effect of dopamine [after 2 h application
of either cycloheximide (H) or vehicle ()] at each time point was
normalized by subtracting the change in firing rate (%) at the 5-min time
point. No reversal of dopamine-induced inhibition was observed when
cycloheximide was present in the micropipettes.
there was a significant difference between the cycloheximide and
DMSO groups with an interaction of pipette-contents with time
[two-way repeated measures ANOVA, F (3,24)= 3.90, p< 0.03]
and the Tukey post hoc test indicated that there was a signifi-
cant difference between the groups at the 115 min time point
(p< 0.05).
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Similarly, we tested whether cycloheximide would prevent
DIR as Gq shRNA had done in our lentivirus experiments. For
these studies, we again included cycloheximide (800µM) in the
recording pipettes. Before testing DIR, a 120-min pre-incubation
period was given to allow the cycloheximide to diffuse from the
pipette into the surrounding tissue, as was done in the shRNA
experiments. An example of an experiment in which this protocol
was used is shown in Figure 3C. After the 120-min incubation
period, dopamine (3.5µM) was added to the superfusate, and
administered for 40 min. No reduction in the inhibition produced
by dopamine was apparent over the 40-min time course. However,
a decrease in the inhibitory effect of dopamine was observed when
cycloheximide was not present (Figure 3D), indicative of DIR. The
pooled data from experiments similar to Figures 3C,D is shown in
Figure 3F. There was a significant difference between the cyclohex-
imide and DMSO groups with an interaction of pipette-contents
with time [two-way repeated measures ANOVA, F (7,49)= 7.79,
p< 0.001] and Tukey post hoc test indicated that there was a sig-
nificant difference between the groups at each time point from
15 to 40 min (p< 0.05). These results indicate that cycloheximide
prevented the development of DIR.
DISCUSSION
Inclusion of agents in extracellular recording micropipettes is a
method which uses small amounts of those agents and permits
delivery to the vicinity of the neuron whose activity is being
recorded. We have used this method with some success with a
number of conventional pharmacological agents (Nimitvilai et al.,
2012c). The results presented above indicate that inclusion of
shRNA directed against Gq can reduce the effect of an agonist
(NT) that is thought to produce excitation through activation of
Gq (Seutin et al., 1989; Grisshammer and Hermans, 2001). In
addition, we used this method to obtain information to support
the idea that DIR is also mediated by Gq. While RNA and protein
synthesis can take longer amounts of time, we found that there was
sufficient time within a long recording period (2 h) to produce a
significant effect on the response to NT. While we cannot estimate
the actual degree of suppression of Gq in the region around the
recording pipette, it has been reported that the half-life of degra-
dation of Gq is short (about 3 h) in CHO cells with the addition of
Gq-linked agonist. The effect of suppression of protein synthesis
using a more general protein synthesis inhibitor (cycloheximide)
supports the idea that suppression of protein synthesis (specifi-
cally or generally) can decrease electrophysiological responses to
agonists within the time frame of an electrophysiological record-
ing. General suppression of protein synthesis would be expected
to have a variety of effects on cell function; what is interesting and
relevant in this case is that suppression of Gq-related processes
by cycloheximide was similar to inhibition of Gq processes fol-
lowing exposure to Gq shRNA. Our studies suggest that it may be
possible to target certain proteins within cells very specifically and,
in addition, to witness the time course of alteration of responses
as a result of downregulation of expression induced by shRNA.
In support of this technique, it has been shown that delivery
of double-stranded siRNA via a patch pipette in VTA neurons in
brain slices could suppress the translation of GluR2 mRNA, result-
ing in a suppression of glutamate responses attributed to GluR2
activity (Mameli et al., 2007). The difference in the method used
in the present report is the use of a lentiviral vector. As we did not
have access to the intracellular compartment, the use of a carrier
for moving the shRNA into the cell was required. Interestingly, in
Mameli’s study, reduction of GluR2 was observed within 20 min,
supporting the relatively rapid turnover of at least some proteins
in VTA neurons maintained in brain slices.
Full suppression of NT-induced excitation was not achieved by
any of these methods, suggesting a limit in the levels of suppression
that could be achieved by blocking protein synthesis. Similarly, it
has been reported in a pulse-chase study that there was a rela-
tively rapid degradation of 60% of Gq, and that it took about
25 h to reduce Gq by an additional 20% (Johansson et al., 2005).
Partial suppression of NT-induced excitation could reflect a par-
tial reduction in Gq. On the other hand, DIR did appear to be
completely suppressed. One factor could be that a portion of the
NT activation of DA VTA neurons is not mediated by Gq, as the
literature suggests that NT can inhibit (Gailly et al., 2000; Najimi
et al., 2002) or stimulate (Yamada et al., 1993; Skrzydelski et al.,
2003) adenylyl cyclase through its interaction with Gi and Gs,
respectively, in some cell types. Alternatively, it may be that DIR is
more sensitive to reduction of Gq than is NT-induced excitation,
and may be completely disrupted by a partial suppression of Gq
function.
One factor that should be noted in these experiments is the
high multiplicity of infection (MOI) involved in these studies.
The amount of vector within the pipette was approximately 4600
particles; we do not know what percentage of this load left the
pipette to interact with the tissue. In addition, we have no way of
knowing how many cells in addition to the neuron from which we
are recording receive the lentivirus, but this method provides a rel-
atively low-cost opportunity for a much higher MOI than would
be achieved normally with intracranial injection of similar lentivi-
ral particles. This high MOI could influence the efficiency with
which the shRNA is delivered to the neuron, and may account for
the fact that there was suppression of Gq-related processes within
2 h. Complex experiments may be necessary to reveal the degree
of suppression of Gq, and the relationship between MOI and the
results observed in the present experiments.
There may be many processes by which introduction of Gq
shRNA may alter Gq mediated responses. Suppression of protein
synthesis and reduction in incorporation of Gq protein into com-
plexes involved in transduction of NT receptor stimulation is the
most direct possibility (Burnett and Rossi, 2012). On the other
hand, there may be regulatory processes within the neuron that
are sensitive to shRNA (Bridge et al., 2003; Snove Jr. and Rossi,
2006), and may trigger other mechanisms of suppression of sig-
nal transduction that could occur more quickly than the processes
involved in turnover of Gq protein. Alternatively, the Gq shRNA
may have a relevant off-target effect, different from an off-target
effect of Golf, that could interfere with DIR. Extensive additional
studies will be needed to establish the degree of suppression of
Gq under the conditions of the experiments described above, and
whether that can fully account for the inhibition of NT-induced
excitation and antagonism of DIR.
Similarly, we do not know that the shRNA affected the neurons
from which we recorded specifically. Effects could have been due to
actions on other neurons in the preparation, including GABergic
neurons (Steffensen et al., 1998), or even glia within the brain slice.
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Extensive studies will be necessary to examine the spread of the
shRNA and the specific cell types affected, and the relationship of
those cells to the firing rate of pDAergic neurons of the VTA.
Here we present the method of inclusion of shRNA in a vector
within the recording pipette in extracellular experiments; it offers
a highly specific and useful way to examine the contribution of
cellular factors to intracellular mechanisms. It is relatively inex-
pensive (as smaller amounts of lentiviral particles are required
per experiment) and offers the opportunity to examine the time
course of suppression of responses (as we did with NT-induced
excitation).
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